Committee debates psychedelic‑assisted therapy pilot for veterans; sponsors say bill preserves ongoing research
Loading...
Summary
Lawmakers discussed SB191, a time‑limited pilot designed to prevent enrolled veterans from losing access to psychedelic‑assisted therapies if FDA approval proceeds; members praised the potential benefits but asked whether state programs should intervene before FDA processes conclude.
The committee took up Senate Bill 191, which sponsors described as narrowly aimed at preserving ongoing pilot research for veterans and others enrolled in clinical programs for severe PTSD or depression. Chair (S5) said the bill does not legalize drugs or create new approvals — rather, it prevents enrolled participants from losing access to treatment if an FDA approval or regulatory change would otherwise stop the study.
Representative Mara (S13) and Senator Summers (S11) expressed concern about the interplay between state‑funded pilots and the national FDA approval process. "If it becomes FDA‑approved, then veterans can move over to an FDA‑approved drug," Mara said, asking why state action was necessary. Proponents replied that the bill contains no funding and is time‑limited; its core intent is to avoid an abrupt stop to care for people already enrolled in research studies. One proponent said clinicians and veterans raised concerns that treatment continuity would be disrupted by the prior statutory language and that the committee was seeking to preserve the clinical study's continuity without endorsing unapproved uses.
Senator Summers noted that some drugs in this area have been designated 'breakthrough therapy' and are on an accelerated FDA pathway, but said implementation through insurance and formularies can lag — one reason supporters want to bridge care continuity now. "As soon as you clear a drug, that doesn't mean that insurance is gonna pick it up on their formulary," Summers said, and she indicated support for moving forward while monitoring implementation.
The committee moved the bill and conducted a roll‑call procedure; transcript indicates votes were recorded and left open while clerks completed tabulation.
Why it matters: The bill seeks to square two realities: the slow federal approval and coverage process and the immediate clinical needs of people, particularly veterans, already enrolled in pilot programs. Sponsors stressed the protection is limited to preserving existing research participation and continuity of care.
What happens next: The committee conducted a procedural roll‑call and left votes open; proponents said the measure is time‑limited and carries no new state appropriation.
